News Sentiment

QNCX sentiment intelligence

Quince Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed

Weighted score 56 Balanced news tone 57 relevant articles

Exchange NASDAQ United States

Sector Healthcare Market context

Industry Biotechnology Read-through group

Latest close 18.88 Week of 17 Jul 2026

Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+7.6% over one week, -0.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Quince Therapeutics updates its strategy as a clinical-stage biotech. QNCX focuses on targeted drug

Market Reaction

Price moving ahead of tone

63/100 confidence

Primary event Market update 75/100 classification

One-week reaction 7.6% Price confirming higher

Trend fit Trend inactive -0.1% over four weeks

Fair value -92.2% Below fair value

Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance

Positive 13

Neutral 41

Negative 3

Relevance

Why the article matched

Direct first

Direct company coverage 49

Industry context 8

Sector context 0

Sources

Coverage mix

Publishers

Stock Titan 10

Market source 7

Investing.com 6

TradingKey 6

Moomoo 4

GlobeNewswire 4

TradingView 4

simplywall.st 3

Event Lens

What the news is about

Classified themes

Market update 23

Earnings 14

Deals and strategy 10

Analyst action 6

Regulatory and legal 2

Guidance 1

Balance sheet 1

Sentiment Trail

Score over time

50 baseline

Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-57 of 57

TradingKey Direct company coverage

Quince Therapeutics Inc (QNCX) Institutional Confidence

This article provides details on the institutional confidence in Quince Therapeutics Inc (QNCX), including current share price, market capitalization, and P/E ratio. It lists the top institutional shareholders, their shareholdings, and the percentage change in their positions. Th

Tone: Neutral 50/100
Event: Market update
Published: 17 Jun 2026 08:09
Source: TradingKey

Stock Titan Direct company coverage

Quince Therapeutics (QNCX) director receives 2,700 stock options grant

Tone: Neutral 50/100
Event: Market update
Published: 15 Jun 2026 07:00
Source: Stock Titan

Stock Titan Direct company coverage

Quince Therapeutics (QNCX) director granted stock options for 2,700 shares

Tone: Neutral 50/100
Event: Market update
Published: 15 Jun 2026 07:00
Source: Stock Titan

Stock Titan Direct company coverage

Quince Therapeutics (NASDAQ: QNCX) wins approval for wide reverse split range

Tone: Neutral 50/100
Event: Regulatory and legal
Published: 11 Jun 2026 07:00
Source: Stock Titan

Market source Direct company coverage

Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy

Tone: Positive 66/100
Event: Market update
Published: 02 Jun 2026 07:00
Source: Market source

GlobeNewswire Direct company coverage

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

Tone: Neutral 50/100
Event: Market update
Published: 18 May 2026 14:21
Source: GlobeNewswire

GlobeNewswire Direct company coverage

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

Tone: Neutral 50/100
Event: Market update
Published: 18 May 2026 13:26
Source: GlobeNewswire

GlobeNewswire Direct company coverage

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

Tone: Neutral 50/100
Event: Deals and strategy
Published: 18 May 2026 13:26
Source: GlobeNewswire

simplywall.st Industry context

There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings

Tone: Negative 34/100
Event: Earnings
Published: 15 May 2026 07:00
Source: simplywall.st

Market source Industry context

Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings

Tone: Neutral 50/100
Event: Earnings
Published: 14 May 2026 07:00
Source: Market source

simplywall.st Industry context

Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results

Tone: Positive 66/100
Event: Earnings
Published: 11 May 2026 07:00
Source: simplywall.st

Market source Industry context

Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00

Tone: Neutral 50/100
Event: Earnings
Published: 11 May 2026 07:00
Source: Market source

Market source Industry context

Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

Tone: Neutral 50/100
Event: Earnings
Published: 25 Apr 2026 07:00
Source: Market source

Market source Industry context

Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)

Tone: Neutral 50/100
Event: Earnings
Published: 21 Apr 2026 07:00
Source: Market source

The Globe and Mail Direct company coverage

Quince Therapeutics Announces 1-for-10 Reverse Stock Split

Tone: Neutral 50/100
Event: Market update
Published: 10 Apr 2026 07:00
Source: The Globe and Mail

Stock Titan Direct company coverage

A $5.5M payment erased Quince debt as it explores merger options

Tone: Neutral 50/100
Event: Deals and strategy
Published: 30 Mar 2026 07:00
Source: Stock Titan

Sahm Direct company coverage

What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours

Tone: Neutral 50/100
Event: Market update
Published: 18 Feb 2026 15:18
Source: Sahm

Stock Titan Direct company coverage

Lead drug failure leaves Quince (QNCX) banking on reverse merger

Tone: Neutral 50/100
Event: Deals and strategy
Published: 12 Feb 2026 08:00
Source: Stock Titan

Investing.com Direct company coverage

Quince Therapeutics stock plummets after revealing strategic alternatives

Tone: Neutral 50/100
Event: Market update
Published: 12 Feb 2026 08:00
Source: Investing.com

Sahm Direct company coverage

Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks

Tone: Negative 34/100
Event: Deals and strategy
Published: 12 Feb 2026 08:00
Source: Sahm

The Business Journals Direct company coverage

Quince stock plunges 95% following failed clinical trial for inherited childhood disease

Tone: Neutral 50/100
Event: Market update
Published: 02 Feb 2026 08:00
Source: The Business Journals

Investing.com Direct company coverage

Quince Therapeutics stock tumbles after failed Phase 3 trial results

Tone: Neutral 50/100
Event: Earnings
Published: 29 Jan 2026 08:00
Source: Investing.com

Stock Titan Direct company coverage

Rare disease hope stalls as eDSP trial fails and Quince halts development

Tone: Neutral 50/100
Event: Market update
Published: 29 Jan 2026 08:00
Source: Stock Titan

simplywall.st Direct company coverage

Is Quince Therapeutics (NASDAQ:QNCX) Using Debt Sensibly?

Tone: Neutral 50/100
Event: Balance sheet
Published: 21 Jan 2026 08:00
Source: simplywall.st

Business Wire Direct company coverage

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Tone: Neutral 50/100
Event: Market update
Published: 12 Jun 2025 07:00
Source: Business Wire

Stock Titan Direct company coverage

Quince (QNCX) Stock Price, News & Analysis

Tone: Neutral 50/100
Event: Market update
Published: 25 Apr 2025 00:36
Source: Stock Titan

MarketBeat Direct company coverage

Quince Therapeutics (QNCX) Stock Price, News & Analysis

Tone: Neutral 50/100
Event: Market update
Published: 04 Aug 2022 13:01
Source: MarketBeat